Biotechnology-Based Evvy Raises $40M in Series B Funding

The round also saw participation from Rethink Impact, Muse Capital, Alumni Ventures, LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures.

The company plans to use the funding to validate new AI driven diagnostic and care models across womens health conditions, starting with fertility. It will also expand distribution through physician and partner channels and deepen its collaboration with US Fertility.

What is Evvy?

Evvy is a precision medicine platform focused on womens health, with a particular focus on the vaginal microbiome.

The company has developed a proprietary clinical-grade dataset on the vaginal microbiome and women's health outcomes, along with EvvyAI, its machine learning engine that analyzes biological data.

Read More:Biotech Research RegCell Raises $66M in Total Funding

Evvy provides at-home testing, personalized treatment, and long-term biomarker tracking. Its tests use CLIA certified and NYS CLEP-approved metagenomic sequencing, with results ordered and interpreted by licensed clinicians.

How Much Funding Has Evvy Raised?

Evvy has raised $40 million in it's latest Series B funding round.  

The round was led by Catalio Capital Management and included several existing and new investors.

The provided information does not state Evvy's total funding raised after the Series B round or details of previous funding rounds.

Who Invested in Evvys Series B Round?

The Series B was led by Catalio Capital Management.

Participating investor's included:

• Rethink Impact
• Muse Capital
• Alumni Ventures
• LabCorp Venture Fund
• General Catalyst
• Left Lane Capital
• BBG Ventures
• Amboy Street Ventures
• Ingeborg
• Foreground Capital
• Flywheel Ventures

Why the Funding Matters

Evvy plans to use the new funding to validate AI-driven diagnostic and care models across women's health, beginning with fertility.

The company will also expand distribution through physician and partner channels and strengthen its collaboration with US Fertility.

Who founded Evvy?

Evvy was founded by Priyanka Jain, Laine Bruzek, and Pita Navarro.

The company is based in New York City.

Market and Business Growth

Evvy says it serves more than 100,000 patients and 3,000 practitioners through its testing and care platform.

The company says its proprietary dataset has contributed to 13 peer-reviewed publications and abstracts, the identification of novel bacterial vaginosis subtypes, and the discovery of hundreds of previously uncatalogued vaginal microbiome genomes.

According to Evvy, its clinicians using the platform and EvvyAI can provide a diagnosis to more than 90% of symptomatic patients and achieve an approximately 50% or greater reduction in bacterial vaginosis recurrence through targeted treatment protocols.

The company's Vaginal Health Test can identify more than 700 microbes using a single at-home swab.

What Happens Next?

Evvy will focus on validating new AI-driven diagnostic and care models, starting with fertility.

The company will also expand its physician and partner distribution channels and continue working with US Fertility to develop its women's health platform.

Read More:Wisconsin-Based Retham Technologies Raises $1.5M in Seed Funding